Eve decentralizes embryo culture to expand fertility-treatment capacity across Asia-Pacific — built for the secondary cities and underserved regions conventional lab infrastructure does not reach.
Fertility care is constrained not by demand but by infrastructure — the embryology laboratory every conventional IVF cycle depends on. Eve exists to lift that constraint. By relocating the multi-day culture phase out of the lab, EVEA™ lets established operators raise throughput from the footprint they already have, and lets new entrants launch services without building a cleanroom. Our focus is Asia-Pacific, and in particular the secondary cities and underserved regions conventional infrastructure has never reached.
Eve provides the device, protocols and quality systems that let a hospital run an intravaginal-culture service line — and earns as that service line grows. The platform is built to be deployed and replicated, not operated by us.
Eve develops EVEA™, an intravaginal culture device, and the activation platform around it — built to medical-device regulatory and manufacturing standards.
Eve earns a recurring per-cycle platform fee. We grow as our partners run more cycles — our incentives are aligned with theirs.
One activation model, deployed site by site across Asia-Pacific — recurring on participation rather than tied to infrastructure we own.
Eve is led by a team combining deep MedTech commercial experience with clinical and regulatory expertise — Founder & CEO Yve Lyppens and Co-Founder & Director of Medical Affairs Col. Dr. Othman Sukhilmi.
Meet the team →Eve Fertility Ltd. is incorporated in Hong Kong SAR, with an active deployment pipeline across Asia-Pacific — the secondary-city hospital systems where fertility infrastructure does not yet exist.
For hospital systems, fertility operators, investors, regulators and partners across Asia-Pacific.
Request a briefing → Explore EVEA™